Download the Case Study
A Pivotal Phase III Trial for a New Class of Antibiotic for the Treatment of Uncomplicated UTIs
A Pivotal Phase III Trial for a New Class of Antibiotic for the Treatment of Uncomplicated UTIs
Strategic Approaches to Achieving Rapid Site Start-Up and FDA Approval in a Phase III UTI Study
In a newly released case study, Medpace experts explore strategic approaches to achieving rapid site start-up and FDA approval in Urinary Tract Infection (UTI) trials.
In this Phase III registrational trial for a new class of antibiotic for the treatment of uncomplicated UTIs, Medpace was able to surpass the site activation goal, complete enrollment ahead of schedule, and achieve regulatory goals.
